Finally, to investigate the renoprotective effect of FXa inhibitors, including edoxaban, in real-world clinical practice, we used the FAERS database to estimate the occurrence of tubulointerstitial nephritis in patients treated with two types of anticoagulant drugs: FXa inhibitors and warfarin. The gene discussed is F10; the disease is interstitial nephritis.